KAINOS Laboratories (TSE:4556) Debt-to-Equity : 0.13 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is KAINOS Laboratories Debt-to-Equity?

KAINOS Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円540 Mil. KAINOS Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円250 Mil. KAINOS Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円6,183 Mil. KAINOS Laboratories's debt to equity for the quarter that ended in Dec. 2023 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for KAINOS Laboratories's Debt-to-Equity or its related term are showing as below:

TSE:4556' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13 Med: 0.27 Max: 0.5
Current: 0.13

During the past 13 years, the highest Debt-to-Equity Ratio of KAINOS Laboratories was 0.50. The lowest was 0.13. And the median was 0.27.

TSE:4556's Debt-to-Equity is ranked better than
62.96% of 710 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs TSE:4556: 0.13

KAINOS Laboratories Debt-to-Equity Historical Data

The historical data trend for KAINOS Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KAINOS Laboratories Debt-to-Equity Chart

KAINOS Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.28

0.23

0.22

0.18

0.17

KAINOS Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.17	0.17	0.15	0.13	0.13

Competitive Comparison of KAINOS Laboratories's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KAINOS Laboratories's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where KAINOS Laboratories's Debt-to-Equity falls into.

KAINOS Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

KAINOS Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(480.389	+	460.707)	/	5669.838
	=	0.17

KAINOS Laboratories's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(540	+	250)	/	6182.781
	=	0.13

KAINOS Laboratories (TSE:4556) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

KAINOS Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of KAINOS Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

KAINOS Laboratories (TSE:4556) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KAINOS Laboratories Inc (TSE:4556) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

38-18, Hongo 2-chome, Bunkyo-ku,, Tokyo, JPN

Website

http://www.kainos.co.jp

KAINOS Laboratories, Inc. is focused on development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sale and export/import of physicochemical measuring equipment for medical use.

KAINOS Laboratories (TSE:4556) Headlines

No Headlines